This morning we watched ICON Public rise 4.3% to a price of $224.73 per share. The Large-Cap Biotechnology company is now trading -17.05% below its average target price of $270.94. Analysts have set target prices ranging from $232.0 to $295.0 per share for ICON Public, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.8%, and a short ratio of 1.09. The company's insiders own 0.65% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.3% of ICON Public's shares being owned by this investor type.
Institutions Invested in ICON Public
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | WCM Investment Management, LLC | 8% | 6,654,257 | $1,495,411,147 |
| 2024-09-30 | Massachusetts Financial Services Co. | 5% | 4,063,771 | $913,251,239 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 4% | 3,350,582 | $752,976,278 |
| 2024-09-30 | Wellington Management Group, LLP | 4% | 3,081,973 | $692,611,779 |
| 2024-09-30 | Ninety One UK Ltd | 3% | 2,696,402 | $605,962,409 |
| 2024-09-30 | Lazard Asset Management LLC | 3% | 2,360,061 | $530,376,498 |
| 2024-09-30 | Boston Partners | 3% | 2,284,684 | $513,437,025 |
| 2024-09-30 | FMR, LLC | 3% | 2,190,307 | $492,227,682 |
| 2024-09-30 | Capital Research Global Investors | 2% | 1,901,721 | $427,373,752 |
| 2024-09-30 | Invesco Ltd. | 2% | 1,836,820 | $412,788,550 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on ICON Public.
